公开(公告)号：US20250025531A1

公开(公告)日：2025-01-23

申请号：US18751087

申请日：2024-06-21

Applicant: Regeneron Pharmaceuticals, Inc. ,  Bayer HealthCare LLC

Inventor： Robert L. Vitti ,  Alyson J. Berliner ,  Karen W. Chu ,  Friedrich Asmus ,  Sergio Casimiro da Silva Leal ,  Thomas Eißing ,  Kay D. Rittenhouse

IPC: A61K38/17 ,  A61K9/00 ,  A61K47/02 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61P27/02

Abstract: The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, DR and DME characterized by high doses of aflibercept extended periods between doses.

公开(公告)号：US20230302085A1

公开(公告)日：2023-09-28

申请号：US18021802

申请日：2022-05-16

Applicant: Regeneron Pharmaceuticals, Inc. ,  Bayer HealthCare LLC

Inventor： Robert L. Vitti ,  Alyson J. Berliner ,  Karen Chu ,  Friedrich Asmus ,  Sergio Casimiro da Silva Leal ,  Thomas Eißing ,  Kay D. Rittenhouse

IPC: A61K38/17 ,  A61P27/02

CPC classification number: A61K38/179 ,  A61P27/02

Abstract: The present invention relates to treatment regimens characterized by high doses of aflibercept (e.g., 8 mg) and extended intervals between doses (e.g., 12 weeks) with improved visual and anatomic outcomes relative to treatment with lower doses such as 2 mg.

公开(公告)号：US20240024420A1

公开(公告)日：2024-01-25

申请号：US18121499

申请日：2023-03-14

Applicant: REGENERON PHARMACEUTICALS, INC. ,  BAYER HEALTHCARE LLC

Inventor： Robert L. Vitti ,  Alyson J. Berliner ,  Karen Chu ,  Friedrich Asmus ,  Sergio Casimiro da Silva Leal ,  Thomas Eißing ,  Kay D. Rittenhouse

IPC: A61K38/17 ,  A61K9/00 ,  A61P27/02

CPC classification number: A61K38/179 ,  A61P27/02 ,  A61K9/0048

Abstract: The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, characterized by high doses of aflibercept and extended intervals between doses.

公开(公告)号：US20230295266A1

公开(公告)日：2023-09-21

申请号：US18121490

申请日：2023-03-14

Applicant: REGENERON PHARMACEUTICALS, INC. ,  BAYER HEALTHCARE LLC

Inventor： Robert L. Vitti ,  Alyson J. Berliner ,  Karen Chu ,  Friedrich Asmus ,  Sergio Casimiro da Silva Leal ,  Thomas Eißing ,  Kay D. Rittenhouse

IPC: C07K14/71 ,  A61P27/02

CPC classification number: C07K14/71 ,  A61P27/02 ,  C07K2319/30

Abstract: The present invention relates to regimens for the treatment of angiogenic eye disorders such as DR and DME characterized by high doses of aflibercept and lengthening intervals between doses.